1.80Open1.80Pre Close0 Volume10 Open Interest2.50Strike Price0.00Turnover584.98%IV42.38%PremiumAug 16, 2024Expiry Date0.52Intrinsic Value100Multiplier24DDays to Expiry1.28Extrinsic Value100Contract SizeAmericanOptions Type0.8127Delta0.0585Gamma1.68Leverage Ratio-0.0255Theta0.0004Rho1.36Eff Leverage0.0021Vega
Organogenesis Stock Discussion
of $2.3 million compared to net revenue of $107.6 million for the first
quarter of 2023. Net revenue for the first quarter of 2024 consists of:
-- Net revenue from Advanced Wound Care products of $103.9 million,
an increase of 3% from the first quarter of 2023.
-- Net revenue from Surgical & Sports Medicine products of $6.1
million, a decrease of 9% from the first quarter of 2023.
-- Net loss of ...
Organogenesis Holdings Inc., a frontrunner in the regenerative medicine landscape, has recently shared groundbreaking results from its Phase 3 clinical trial for ReNu®, a cutting-edge therapy designed for knee osteoarthritis (OA) management. The trial's positive top line data underscore a pivotal moment in pain management and regen...
NEWS
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
Organogenesis announced positive top-line data from its Phase 3 clinical trial of ReNu for knee osteoarthritis, achieving a statistically significant reduction in knee pain and maintenance of function at six months. The results open a transformative opportunity for Organogenesis to enter the pain management market. ReNu addresses a critical unmet medical need for knee ...
NOT EAGLES FOOD FOR GOOSE, DUCK AND CHICKEN... 😋
No comment yet